争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 3 条
2021
医学专家警告不要在斯里兰卡使用国药疫苗
问题披露
医学专家协会警告不要在斯里兰卡使用国药疫苗,理由是专家小组认为现有数据不足以判断其安全性、有效性和免疫原性。
来源摘录
In the backdrop of an independent panel of medical experts cautioning against administering the controversial Chinese manufactured Covid-19 Sinopharm jab over “safety and efficacy” concerns, a key body of eminent medical specialists last week warned of the adverse fallout of using an unproven vaccine in Sri Lanka.
“As the expert medical panel concluded there was insufficient data provided to make a determination on the safety, efficacy and immunogenicity of the Sinopharm vaccine, it was accordingly concluded that this vaccine should not be used in Sri Lanka under the present circumstances”, Dr. Lalantha Ranasinghe, the president of the prestigious body of medical professionals, said.
2017
武汉生物制品研究所生产的一批次百白破疫苗不合格
中国监管部门抽检发现,国药集团武汉生物制品研究所生产的一批次百白破疫苗效价不符合要求。监管部门通报,受影响疫苗为400,520剂。通报称,原因是灌装设备临时故障导致疫苗混悬液不均匀。未使用的疫苗被召回并销毁,该子公司被罚款,并被要求加强设备维护、灌装程序、培训和质量控制。
2017年百白破疫苗效价不合格事件